本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
ZHUBEI, April 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology Co., Ltd. ("Brain Navi") has officially begun IPO counseling with First Securities Inc., marking a strategic step toward accessing the capital markets and advancing its long-term growth in the surgical robot technology industry. Dr. Jerry Chen, CEO of Brain Navi, announced the IPO Consulting to enter the capital market. Founded in 2015 and located in the Hsinchu Biomedical Science Park, Brain Navi concentrates on innovating surgical robots and medical devices. By integrating machine vision, artificial intelligence (AI), and advanced navigation technologies, the company provides high-precision surgical solutions tailored to meet the evolving needs of modern healthcare. Over the years, Brain Navi has established strong partnerships with leading medical institutions worldwide. Its innovations have garnered multiple international patents and regulatory approvals, with global expansion efforts already underway in Europe, Asia, Latin America, and soon in the USA market. The company's flagship product, NaoTrac, is a neurosurgical navigation robot that combines AI, robotics, and computer vision to enhance surgical precision and reduce operative time. Brain Navi's portfolio also includes the KrystoLens, the single-use neuro-endoscope designed to improve safety and efficiency in minimally invasive brain surgery. Looking ahead, Brain Navi plans to deepen collaborations with top-tier medical centers to refine its intelligent surgical systems. Through this IPO counseling process, the company aims to responsibly accelerate R&D and scale its innovations for broader clinical adoption, reinforcing its position as a next-generation leader in smart medical technology. First Securities Inc. expressed confidence in Brain Navi's growth potential. As global interest in surgical robotics continues to rise—especially in neurosurgery, where accuracy is critical—technologies that combine navigation and AI are poised to play a transformative role. The firm will provide continued guidance throughout Brain Navi's IPO journey, helping bring new investment opportunities to those who share a vision for the future of intelligent healthcare.
In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied. HSINCHU, April 17, 2025 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, announced the preliminary results of a research collaboration with the National Taiwan University Hospital (NTUH) on breast cancer patients. The study found that JelloX's 3D pathology technology identified a significantly increased proportion of tumors with HER2-low and HER2-ultralow expression compared to conventional methods, demonstrating this technology's increased sensitivity and potential as a superior diagnostic tool for HER2 detection in breast cancers. This is a 3D fluorescent-stained image of mammary ducts from a breast cancer patient. Green areas indicate drug-targeted receptors. Unlike traditional 2D pathology, this reveals the spatial distribution of receptors, reducing the risk of misjudging treatment decisions. Contact JelloX at sales@jellox.com to explore partnerships and learn more about the company's cutting-edge 3D pathology technology. According to the US National Cancer Institute, breast cancer is the most prevalent form of cancer. However, the difficulty of precisely determining treatment has made the identification of HER2 expression essential. In HER2-low and HER2-ultralow metastatic breast cancer, the novel antibody-drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) has demonstrated robust efficacy over conventional chemotherapy. Yet considering HER2 spatial heterogeneity, traditional diagnostic methods have shown to be less precise than 3D pathology in detecting the presence of the HER2 protein. "For the specific challenges posed by metastatic breast cancer and the need to identify predictive biomarkers accurately, the high sampling capacity of 3D pathology holds particular potential," commented Dr. Yen-Yin Lin, CEO of JelloX. "JelloX Biotech's Comprehensive HER2 Diagnostic Solution is poised to revolutionize HER2 diagnostics. With a more comprehensive data set on tumor samples, healthcare providers can be empowered to make more precise diagnoses, ensuring that the right patients receive the right treatment at the right time." New findings with NTUH on HER2 breast cancer In JelloX's research collaboration with NTUH, preliminary findings indicate that more than half of the analyzed cases exhibited diagnostic discrepancies when re-evaluated using the company's advanced 3D pathology methods. Notably, among patients initially classified as HER2-null by traditional methods, more than 66.7% were reclassified as HER2-expressing (HER2-low or HER2-ultralow) using 3D technology, thereby becoming potentially eligible for T-DXd treatment. These findings echo the company's recent results using samples from colorectal and esophageal cancers, demonstrating that 3D pathology may have broader potential across various cancer types. The full findings will be shared at the Global Breast Cancer Conference in South Korea on April 17. https://gbcc.kr/Main.asp Implications for breast cancer treatment and drug guidelines T-DXd has demonstrated significant efficacy in tumors with HER2 expression. However, tumors classified as HER2-null under conventional pathological testing are ineligible for T-DXd treatment. By detecting HER2 more precisely using 3D pathology methods, we can identify more patients eligible for T-DXd therapy. In addition to cancer patients, JelloX's 3D pathology technology has the potential to expand possibilities across healthcare stakeholders: For physicians: This advanced diagnostic tool offers a more comprehensive patient data set and, when integrated with AI, helps reduce physician workloads. For pharmaceutical companies and research institutions: The technology enhances companion diagnostics (CDx) for drug usage and is a valuable tool for new drug development. For healthcare systems: 3D pathology optimizes medical resource allocation and minimizes unnecessary financial and healthcare burdens. About JelloX Biotech Inc. Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a startup that focuses on advancing cancer pathology through 3D digital imaging and AI technology. For more information, please visit: https://jellox.com/en/home/
(台灣新竹，2025年04月11日)，隨著電動車、5G 通訊與 HPC 快速發展，化合物半導體材料如 SiC 和 GaN 具備高頻率、耐高壓、優異的散熱性能與高效能轉換特性，成為車用半導體與電源管理 IC 領域關鍵技術。但也面臨高功率元件測試的精準性、3DIC 封裝技術檢測需求及生產效率挑戰。 為了突破高功率類比與混合訊號測試的瓶頸，筑波科技與美商 Teradyne 合作 ETS 測試解決方案。涵蓋從 MA、FA 到車用半導體測試的完整技術支持，以太赫茲技術，實現非破壞性晶圓材料測試與 3DIC 高階封裝檢測，協助產業達成從研發到量產的無縫銜接。 UR/MiR 協作自動化解決方案已成為提升半導體製程效率的關鍵利器，能有效降低人工成本，還能提升檢測與搬運過程的精準性與穩定性。 本次論壇匯聚產學研界專家，共同探討創新應用與未來趨勢。誠摯邀請您至報名網站登記參與。 日期：2025年04月30日 (三) 13:00-16:40 地點：筑波醫電大樓1F 諾貝爾講堂(新竹縣竹北市生醫二路66號) 報名：https://register.acesolution.com.tw/20250430_WBGSemiconductor_Seminar VIP 貴賓/講師陣容/主題： l 鴻海研究院/ 蕭逸楷博士 組長：AI 時代的碳化矽：智慧設計加速功率技術革新 l 筑波科技/ 謝易錚 業務經理：化合物半導體市場趨勢及高功率類比與混合訊號測試創新 l 筑波科技/ 官暉舜博士 研發經理：化合物半導體材料與晶圓測試挑戰與解決方案 l Onsemi 安森美/ 翁紹洋 產品暨市場行銷經理：DrWBG application for AI server l Teradyne Robotics/ 王永廸 商務發展經理：運用 MiR 打造廠區高穩定、無人化配送網絡 精彩展示體驗： l 高功率類比與混合訊號測試方案 l 晶圓材料與 3DIC 非破壞性測試 l 半導體協作 Robots 自動化 聯絡筑波科技 筑波科技股份有限公司ACE Solution, Co., Ltd. 地址：新竹縣竹北市台元街28號2樓之1 電話：03-5500909 電子郵件：service@acesolution.com.tw 網站：https://www.acesolution.com.tw/en/index/ 關於筑波科技（ACE Solution） 筑波科技（https://www.acesolution.com.tw/en/index/）成立於2000年，位於台灣新竹，在中國蘇州和深圳以及越南設有分公司，可提供服務。我們的使命是提供訂製的測試解決方案，以滿足電氣元件、設備和系統製造商的客戶需求，通過合作夥伴提供技術解決方案。我們專注於射頻、毫米波和太赫茲領域，擁有專業的技術支援團隊，提供專業、創新和多功能的綜合技術和解決方案。
HSINCHU, March 25, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a committed Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to announce its participation in CMEF (China International Medical Equipment Fair), held from April 8-11, 2025, at the National Exhibition and Convention Center, Shanghai. Image by ICP DAS-BMP The spotlight of this year's exhibit will be the ARP-93A-B20 WHITE L and ARP-95A-B20 WHITE L, specifically engineered for ureteral stents. These innovative TPU materials meet ISO 10993 standards for biocompatibility, ensuring safety during implantation. They offer exceptional stability in thermal-setting processes with no migration issues, maintaining product reliability. With 15 available colors commonly used in medical devices, they offer versatile design possibilities for manufacturers. Complementing this highlight are other groundbreaking TPU solutions. The Arothane™ ARP-W-G series, contained with 40-60% Tungsten, provides excellent radiopacity for thin-walled medical devices and reliable performance for guidewire coatings. Additionally, the Arothane™ ARP-B20 and Durathane™ ALC-B40, enhanced with Barium Sulfate, deliver certified safety for extended implantation. To meet the demands of a wider range of applications, ICP DAS-BMP also focuses on both softer and harder TPU materials. The Engineering Arothane™ TPU (EARP series), with hardness above 70D, features a high glass transition temperature and exceptional light transmission, making it an ideal choice for high-strength, high-modulus applications such as Luer-Lock connectors. Meanwhile, the soft ARP series, with hardness below 70A, provides enhanced flexibility and adaptability for diverse medical applications, further expanding ICP DAS-BMP's comprehensive TPU portfolio. Visit the ICP DAS-BMP team at Hall 8.1, Booth M49, to explore these advancements and discover tailored TPU solutions designed to elevate healthcare innovations. About ICP DAS-BMPICP DAS-BMP, a leading TPU manufacturer and supplier based in Taiwan, is ISO 13485 certified and operates specialized laboratories focused on quality management. Leveraging over thirty years of industrial automation expertise from its parent company ICP DAS, ICP DAS-BMP employs smart factory practices to enhance product quality and expedite delivery times. The company is committed to responsive after-sales support and flexible solutions, even for small order quantities, ensuring customer satisfaction and fostering long-term partnerships. For more information, please visit: https://bmp.icpdas.com
Hsinchu, Taiwan – March 20, 2025, in an era of rapidly evolving wireless connectivity technologies, ACE Solution successfully held the "Leading the Future of Wireless: Smart Collaboration and Integration" seminar, igniting new opportunities for wireless connectivity and smart factory innovation. Industry experts gathered to discuss the integration of WiFi-7 era intelligent factory automation and wireless testing technologies, sparking AI innovation and ushering in a new chapter of the Internet of Everything. With high-speed transmission and interference among various communication signals posing significant challenges, electromagnetic interference (EMI) has increasingly affected transmission quality. To address these challenges, ACE Solution, in collaboration with LitePoint and Universal Robots, shared innovative tools for precise interference source identification and intelligent testing integration solutions, empowering companies to overcome technological bottlenecks. The seminar commenced with opening remarks by ACE Solution Marketing VP Tony Hsu, who provided an in-depth analysis of market trends and emphasized the impact of wireless technology and innovative collaboration on the industry's future. Featured presentations included ACE Solution GM Frank Chang discussing "Intelligent Test Integration Leading the Future of Wireless," LitePoint Sales Vice General Manager Adonis Lee presenting "Unlocking WiFi-7 to Empower a New Era of IoT and Wireless Connectivity," Universal Robots Business Development Manager Alan Lu sharing "Human-Robot Collaboration: Boosting Production Efficiency and Volumes," ACE Solution Technical Manager Max Hung addressing "Overcoming Electromagnetic Interference for Precise Testing: EMI Challenges and Solutions," and ACE Solution Technical Manager Bruce Cheng summarizing with "Launching Smart Strategies: Integrated Testing of Wireless Products." In addition to the insightful presentations, the seminar featured four interactive exhibition areas where attendees could experience cutting-edge technological solutions firsthand. The showcased areas included Wireless Communication Automation Integrated Testing Solution, Smart Factory Collaborative Automation Solution, EMI Electromagnetic Wave Automated Scanning System, and New Approach to Measurement Instruments – Available for Rental or Purchase. Through practical demonstrations and interactive experiences, participants gained valuable insights into the potential and innovation of these technological applications. The successful conclusion of this seminar showcased ACE Solution's technological leadership in wireless communication and intelligent collaboration. It also provided a valuable platform for industry professionals to enhance their understanding of innovative technologies and foster collaboration. Moving forward, ACE Solution will continue to refine its technologies and services, working hand-in-hand with industry partners to create a new chapter in the era of innovative technologies.
Hsinchu, Taiwan – March 20, 2025 – ACE Biotek unveiled its Spark Surgical Anesthesia System at the 2025 Kaohsiung SmartCity Summit & Expo, featured at the Smart Healthcare Pavilion. The company also participated in the Joint Commission of Taiwan’s “Smart Hospital Leadership Summit,” where it engaged with over a hundred hospital directors across Taiwan, promoting the vision of enhancing healthcare efficiency and reducing labor burdens through innovative healthcare solutions. Themed “Sustainability × AI = The New Future of Smart Healthcare,” the Smart Healthcare Pavilion gathered 18 medical institutions from Southern Taiwan, showcasing innovative achievements in competent healthcare across the central and southern regions. ACE Biotek’s Spark Surgical Anesthesia System, which integrates pre-, intra-, and post-operative anesthesia care forms, aims to enhance the digitalization level of anesthesia departments in hospitals across these regions. The interactive demonstration area attracted numerous healthcare professionals to experience the system firsthand. The event drew officials from various industries, academia, and the healthcare sector to the opening ceremony and nearly 200 international visitors. Many guests, such as Kaohsiung Deputy Mayor Lin Chin-Rong, the Ministry of Health and Welfare Director, Health Bureau representatives, and hospital IT managers, visited the ACE Biotek booth to explore the Spark Surgical Anesthesia System. By leveraging digital technologies, the system achieves structured data management and paperless processes, significantly improving healthcare efficiency and precision in collaboration. Additionally, it offers a comprehensive integration of anesthesia data throughout the surgical process, from physiological monitors to anesthesia machine data, providing real-time recording and seamless data flow. This high-level integration enables smooth interfacing with hospital HIS, surgical systems, and billing systems while combining medical AI and big data to enhance operational efficiency and accuracy, supporting hospitals in achieving efficient and standardized intelligent surgery management. In line with the Ministry of Health and Welfare’s vision for a next-generation digital healthcare platform, ACE Biotek is dedicated to developing practical, innovative hospital solutions tailored for domestic hospitals and promoting them internationally in countries such as Japan, the Middle East, and Southeast Asia. ACE Biotek’s Japan office in Izumi City will hold its grand opening ceremony on April 15, showcasing its commitment to global expansion. ACE Biotek will focus on implementing AI-powered innovative healthcare solutions and collaborating with Japanese medical institutions and partners to bring Taiwan’s imaginative hospital achievements to the international stage. About ACE Biotek Established in 2000, ACE Group has grown across wireless and healthcare industries for more than 20 years. Originally, ACE Group formed ACE Solution as its first foray to focus on wireless communication, networking hardware, and customized system integration projects. Driven by President Steve’s vision to improve healthcare quality, he built the ACE Biotek building from the ground up and officially founded ACE Biotek in 2018. ACE Biotek integrates the past 20 years of industrial experience and knowledge to solve unmet clinical needs. To achieve the early diagnosis of diseases, we have developed innovative medical solutions regarding imaging algorithms, cloud computing, artificial intelligence, and terahertz technology so far. In the long term, ACE Biotek will expand globally to serve as a platform to cultivate talents and support tech companies in transforming into Medtech. Contact ACE Biotek Advanced ACE Biotek Co., Ltd. Address: No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County 302, Taiwan (Hsinchu Biomedical Science Park) Phone: +886-3-5500909 E-mail: service@acebiotek.com Website: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
A12 藝術空間
Hsinchu
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
